{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:55:06Z","timestamp":1790477706126,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpagonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric and Adolescent Gynecology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jpag.2019.04.007","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T04:16:48Z","timestamp":1554956208000},"page":"S23-S29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S","title":["Hormonal Contraceptives, Intrauterine Devices, Gonadotropin-releasing Hormone Analogues and Testosterone: Menstrual Suppression in Special Adolescent Populations"],"prefix":"10.1016","volume":"32","author":[{"given":"Shashwati","family":"Pradhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Gomez-Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpag.2019.04.007_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/IJWH.S46680","article-title":"Menstrual suppression: current perspectives","volume":"6","author":"Hillard","year":"2014","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.jpag.2019.04.007_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/aogs.12036","article-title":"Continuous use of oral contraceptives: an overview of effects and side-effects","volume":"92","author":"Hee","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jpag.2019.04.007_bib3","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2165\/00003495-200464210-00006","article-title":"Long-cycle treatment with oral contraceptives","volume":"64","author":"Wiegratz","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jpag.2019.04.007_bib4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.contraception.2009.05.128","article-title":"Continuous, daily levonorgestrel\/ethinyl estradiol vs. 21-day, cyclic levonorgestrel\/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial","volume":"80","author":"Teichmann","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2019.04.007_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/AOG.0b013e3182a1741c","article-title":"Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive","volume":"122","author":"Archer","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib6","first-page":"CD003989","article-title":"20 \u03bcg versus >20 \u03bcg estrogen combined oral contraceptives for contraception","volume":"8","author":"Gallo","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpag.2019.04.007_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.contraception.2009.07.001","article-title":"Oral contraceptive use and bone density in adolescent and young adult women","volume":"81","author":"Scholes","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2019.04.007_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12902-015-0012-7","article-title":"Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period","volume":"15","author":"Baison","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jpag.2019.04.007_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.AOG.0000175144.08035.74","article-title":"Extended regimens of the contraceptive vaginal ring: a randomized trial","volume":"106","author":"Miller","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.contraception.2009.05.004","article-title":"Extended regimens of the vaginal contraceptive ring: cycle control","volume":"80","author":"Guazelli","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2019.04.007_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.contraception.2006.10.009","article-title":"Bleeding patterns of women using extended regimens of the contraceptive vaginal ring","volume":"75","author":"Barreiros","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2019.04.007_bib12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/01.AOG.0000160430.61799.f6","article-title":"Extended use of transdermal norelgestromin\/ethinyl estradiol: a randomized trial","volume":"105","author":"Stewart","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.contraception.2009.02.008","article-title":"Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons","volume":"80","author":"Hubacher","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2019.04.007_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.contraception.2006.03.008","article-title":"Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg","volume":"74","author":"Arias","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2019.04.007_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jpag.2016.04.001","article-title":"Levonorgestrel-releasing intrauterine device use in female adolescents with heavy menstrual bleeding and bleeding disorders: single institution review","volume":"30","author":"Adeyemi-Fowode","year":"2017","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib16","first-page":"716","article-title":"Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use","volume":"78","author":"R\u00f6nnerdag","year":"1999","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jpag.2019.04.007_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0010-7824(01)00302-X","article-title":"Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years","volume":"65","author":"Hidalgo","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2019.04.007_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14656566.2018.1462337","article-title":"Levonorgestrel-releasing intra-uterine systems as female contraceptives","volume":"19","author":"Grandi","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jpag.2019.04.007_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/17512433.2017.1341308","article-title":"Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years","volume":"10","author":"Nelson","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jpag.2019.04.007_bib20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17425247.2017.1353972","article-title":"LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years","volume":"14","author":"Nelson","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jpag.2019.04.007_bib21","series-title":"Liletta (levonorgestrel-releasing intrauterine system) [package insert]","year":"2015"},{"key":"10.1016\/j.jpag.2019.04.007_bib22","doi-asserted-by":"crossref","first-page":"616.e1","DOI":"10.1016\/j.fertnstert.2011.12.003","article-title":"A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena","volume":"97","author":"Gemzell-Danielsson","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jpag.2019.04.007_bib23","series-title":"Kyleena (levonorgestrel-releasing intrauterine system (19.5) [product monograph])","year":"2018"},{"key":"10.1016\/j.jpag.2019.04.007_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/GCO.0000000000000098","article-title":"Menstrual suppression for adolescents","volume":"26","author":"Altshuler","year":"2014","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib25","first-page":"591","article-title":"Inducement of therapeutic amenorrhea in mentally retarded women: two-year follow-up study","volume":"90","author":"Molsa","year":"1986","journal-title":"Am J Ment Defic"},{"key":"10.1016\/j.jpag.2019.04.007_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0010-7824(90)90077-9","article-title":"Clinical experience with the progestogen-only pill","volume":"42","author":"Broome","year":"1990","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2019.04.007_bib27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.bmt.1701187","article-title":"Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation","volume":"21","author":"Chiusolo","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jpag.2019.04.007_bib28","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/cncr.22199","article-title":"Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate [erratum in 2007; 110:936]","volume":"107","author":"Meirow","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jpag.2019.04.007_bib29","first-page":"537","article-title":"Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate","volume":"42","author":"Laufer","year":"1997","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jpag.2019.04.007_bib30","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3109\/10428190109097723","article-title":"Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study","volume":"42","author":"Lhomme","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jpag.2019.04.007_bib31","first-page":"709","article-title":"Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up","volume":"99","author":"Surrey","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/AOG.0000000000000964","article-title":"Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial","volume":"126","author":"DiVasta","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1933719112438061","article-title":"The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis","volume":"19","author":"Chwalisz","year":"2012","journal-title":"Reprod Sci"},{"key":"10.1016\/j.jpag.2019.04.007_bib34","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/AOG.0000000000001585","article-title":"American college of obstetrics and gynecology committee on adolescent health care: ACOG committee opinion No. 668. Menstrual manipulation for adolescents with physical and developmental disabilities","volume":"128","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib35","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1701-2163(15)30442-4","article-title":"Menstrual suppression in special circumstances","volume":"36","author":"Kirkham","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.jpag.2019.04.007_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5694\/j.1326-5377.2002.tb04315.x","article-title":"Menstrual and contraceptive management in women with intellectual disability","volume":"176","author":"Grover","year":"2002","journal-title":"Med J Aust"},{"key":"10.1016\/j.jpag.2019.04.007_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/JFN.0000000000000124","article-title":"Child sexual abuse revictimization: child demographics, familial psychosocial factors, and sexual abuse case characteristics","volume":"12","author":"Hornor","year":"2016","journal-title":"J Forensic Nurs"},{"key":"10.1016\/j.jpag.2019.04.007_bib38","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/ajmg.a.38219","article-title":"Thyroid dysfunction in patients with Down syndrome: results from a multi-institutional registry study","volume":"173","author":"Lavigne","year":"2017","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jpag.2019.04.007_bib39","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jpag.2019.04.007_bib40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2015.03.006","article-title":"Interactions between hormonal contraception and antiepileptic drugs: clinical and mechanistic considerations","volume":"28","author":"Reimers","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.jpag.2019.04.007_bib41","first-page":"634","article-title":"Effect of antiepileptic drugs on oral contraceptives","volume":"78","author":"Carl","year":"2008","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jpag.2019.04.007_bib42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2147\/IJWH.S102306","article-title":"Transdermal delivery of combined hormonal contraception: a review of the current literature","volume":"9","author":"Galzote","year":"2017","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.jpag.2019.04.007_bib43","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.fertnstert.2007.10.070","article-title":"Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study","volume":"90","author":"Cromer","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jpag.2019.04.007_bib44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpedi.159.2.139","article-title":"Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception","volume":"159","author":"Scholes","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jpag.2019.04.007_bib45","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/01.AOG.0000450758.95422.c8","article-title":"American College of Obstetrics and Gynecology Committee on Adolescent Health Care: ACOG Committee Opinion No. 602. Depot medroxyprogesterone acetate and bone effects","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib46","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/AOG.0b013e31820f387c","article-title":"Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate","volume":"117","author":"Bonny","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib47","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/epi.13559","article-title":"Women with epilepsy initiating a progestin IUD: a prospective pilot study of safety and acceptability","volume":"57","author":"Davis","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpag.2019.04.007_bib48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.contraception.2018.11.018","article-title":"A pilot study of levonorgestrel concentrations and bleeding patterns in women with epilepsy using a levonorgestrel IUD and treated with antiepileptic drugs","volume":"99","author":"Vieira","year":"2019","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2019.04.007_bib49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jmig.2007.04.004","article-title":"Long-term complications of endometrial ablation: cause diagnosis, treatment and prevention","volume":"14","author":"McCausland","year":"2007","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1055\/s-0038-1626710","article-title":"Pregnancy outcomes after endometrial ablation in a multi-institutional cohort","volume":"35","author":"Bauer","year":"2018","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.jpag.2019.04.007_bib51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/1471-0528.14854","article-title":"Pregnancy after endometrial ablation: a systematic review","volume":"125","author":"Kohn","year":"2018","journal-title":"BJOG"},{"key":"10.1016\/j.jpag.2019.04.007_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.AOG.0000452745.44206.c3","article-title":"American College of Obstetrics and Gynecology Committee on Adolescent Health Care: ACOG Committee Opinion No. 606. Options for prevention and management of heavy menstrual bleeding in adolescent patients undergoing cancer treatment","volume":"124","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib53","series-title":"SEER Cancer Statistics Review, 1975-2010","author":"Howlader","year":"2013"},{"key":"10.1016\/j.jpag.2019.04.007_bib54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/pbc.23360","article-title":"The management of menstrual suppression and uterine bleeding: a survey of current practices in the Pediatric Blood and Marrow Transplant Consortium","volume":"59","author":"Adegite","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jpag.2019.04.007_bib55","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpag.2019.04.007_bib56","first-page":"2912","article-title":"GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in\u00a0vitro","volume":"30","author":"Bildik","year":"2015","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jpag.2019.04.007_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000454983","article-title":"Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients: a systematic review and meta-analysis","volume":"12","author":"Bai","year":"2017","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.jpag.2019.04.007_bib58","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/AOG.0b013e31827374e2","article-title":"Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial","volume":"121","author":"Elgindy","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib59","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","article-title":"Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation","volume":"92","author":"Hagglund","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jpag.2019.04.007_bib60","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood.V93.9.3154","article-title":"Hormonal therapy after stem cell transplantation and risk of veno-occlusive disease","volume":"93","author":"Sica","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jpag.2019.04.007_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.beha.2008.12.001","article-title":"Epidemiology of cancer-related venous thromboembolism","volume":"22","author":"Wun","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jpag.2019.04.007_bib62","first-page":"1","article-title":"US medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jpag.2019.04.007_bib63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/sj.bmt.1704577","article-title":"Treatment of menorrhagia in women undergoing hematopoietic stem cell transplant","volume":"34","author":"Amsterdam","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jpag.2019.04.007_bib64","first-page":"CD002126","article-title":"Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding","volume":"4","author":"Lethaby","year":"2005","journal-title":"Cochrane Database Systematic Rev"},{"key":"10.1016\/j.jpag.2019.04.007_bib65","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.21873\/anticanres.11541","article-title":"Continuation of a levonorgestrel intrauterine device during hematopoietic stem cell transplant: a case report","volume":"37","author":"Brady","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jpag.2019.04.007_bib66","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.4158\/1934-2403-23.12.1437","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"23","author":"Hembree","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jpag.2019.04.007_bib67","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/13691058.2016.1182645","article-title":"Queer periods: attitudes toward and experiences with menstruation in the masculine of centre and transgender community","volume":"18","author":"Crisler","year":"2016","journal-title":"Cult Health Sex"},{"key":"10.1016\/j.jpag.2019.04.007_bib68","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1507\/endocrj.EJ12-0319","article-title":"Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder","volume":"60","author":"Nakmura","year":"2013","journal-title":"Endocr J"},{"key":"10.1016\/j.jpag.2019.04.007_bib69","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/trgh.2017.0023","article-title":"The response of the menstrual cycle to initiation of hormonal therapy in transgender men","volume":"2","author":"Ahmad","year":"2017","journal-title":"Transgend Health"},{"key":"10.1016\/j.jpag.2019.04.007_bib70","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/AOG.0000000000000692","article-title":"Effects of cross-sex hormone treatment on transgender women and men","volume":"125","author":"Deutsch","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib71","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1111\/jsm.12698","article-title":"Effects of three different testosterone formulations in female-to-male transsexual persons","volume":"11","author":"Pelusi","year":"2014","journal-title":"J Sex Med"},{"key":"10.1016\/j.jpag.2019.04.007_bib72","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/AOG.0000000000000540","article-title":"Transgender men who experienced pregnancy after female-to-male gender transitioning","volume":"124","author":"Light","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2019.04.007_bib73","doi-asserted-by":"crossref","first-page":"257.e1","DOI":"10.1016\/j.ajog.2018.12.021","article-title":"Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series","volume":"220","author":"Grimstad","year":"2019","journal-title":"Am J Obstet Gynecol"}],"container-title":["Journal of Pediatric and Adolescent Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083318819301809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083318819301809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:46:19Z","timestamp":1761054379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083318819301809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1083318819301809"],"URL":"https:\/\/doi.org\/10.1016\/j.jpag.2019.04.007","relation":{},"ISSN":["1083-3188"],"issn-type":[{"value":"1083-3188","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormonal Contraceptives, Intrauterine Devices, Gonadotropin-releasing Hormone Analogues and Testosterone: Menstrual Suppression in Special Adolescent Populations","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric and Adolescent Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpag.2019.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of North American Society for Pediatric and Adolescent Gynecology.","name":"copyright","label":"Copyright"}]}}